Biodol Therapeutics is a biotechnology company focused on the development of innovative treatments for chronic pain and related neurological conditions. The company leverages its proprietary technology platform to create non-opioid, non-addictive pain management solutions.

BIODOL Therapeutics is a biotech company developing first-in-class compounds for treating chronic pain. It is based on the discovery by Biodol's scientists of the target FLT3, which is a master hub protein in the initiation and maintenance of neuropathic pain (Nature Communications 2018). Morevover, Biodol discovered that its FLT3 breakthrough platform will also help fighting the "Opioid Crisis"​ (patented but yet unpublished). Biodol has a series of FLT3 selective small-molecule extracellular antagonists. The Biodol's FLT3 technological Platform is worldwide protected by 5 patents.

EU:BIODOL

Biodol Therapeutics

Analysis Not Available